SSGJ 626
Alternative Names: SSGJ-626Latest Information Update: 19 Dec 2024
Price :
$50 *
At a glance
- Originator Sunshine Guojian Pharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action CLEC4C protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Systemic lupus erythematosus
Most Recent Events
- 02 Dec 2024 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in China (SC) (NCT06674525)
- 06 Nov 2024 Sunshine Guojian Pharmaceutical plans a phase I trial for Healthy volunteers in November 2024 (SC, Injection) (NCT06674525)
- 06 Nov 2024 Preclinical trials in Systemic lupus erythematosus in China (SC)